| [1] |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108.
|
| [2] |
Forner A, Reig M, Varela M, et al. Diagnosis and treatment of hepatocellular carcinoma. update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH[J]. Med Clin, 2016, 146(11):511.
|
| [3] |
周开梅，郭瑞珍．细胞周期蛋白在恶性肿瘤中的表达[J]．医学综述，2010，16(4):533-536.
|
| [4] |
Passer BJ, Nancy-Portebois V, Amzallag N, et al. The p53-inducible TSAP6 gene product regulates apoptosis and the cell cycle and interacts with Nix and the Myt1 kinase[J]. Proc Natl Acad Sci U S A, 2003, 100(5):2284-2289.
|
| [5] |
Caillot F, Daveau R, Daveau M, et al. Down-regulated expression of the TSAP6 protein in liver is associated with a transition from cirrhosis to hepatocellular carcinoma[J]. Histopathology, 2009, 54(3):319-327.
|
| [6] |
周业庭，吴柏华，徐本文，等．PI3Kp110beta和前强啡肽在人肝癌组织中的表达[J]．中华实验外科杂志，2008，25(11):1399-1400.
|
| [7] |
Hubert RS, Vivanco I, Chen E, et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors[J]. Proc Natl Acad Sci U S A, 1999, 96(25):14523-14528.
|
| [8] |
Ihlaseh-Catalano SM, Drigo SA, de Jesus CM, et al. STEAP1 protein overexpression is an independent marker for biochemical recurrence in prostate carcinoma[J]. Histopathology, 2013, 63(5):678-685.
|
| [9] |
Isobe T, Baba E, Arita S, et al. Human STEAP3 maintains tumor growth under hypoferric condition[J]. Exp Cell Res, 2011, 317(18):2582-2591.
|
| [10] |
韩世愈，王娇．细胞周期蛋白在恶性肿瘤中的表达及其在肿瘤治疗中的作用[J]．分子诊断与治疗杂志，2013(5):357-360.
|
| [11] |
Güller M, Toualbi-Abed K, Legrand A, et al. c-Fos overexpression increases the proliferation of human hepatocytes by stabilizing nuclear Cyclin D1[J]. World J Gastroenterol, 2008, 14(41):6339-6346.
|
| [12] |
Lee TK, Man K, Poon RT, et al. Disruption of p53-p21/WAF1 cell cycle pathway contributes to progression and worse clinical outcome of hepatocellular carcinoma[J]. Oncol Rep, 2004, 12(1):25-31.
|
| [13] |
Wang C, Li Z, Fu M, et al. Signal transduction mediated by cyclin D1: from mitogens to cell proliferation: a molecular target with therapeutic potential[J]. Cancer Treat Res, 2004(119):217-237.
|
| [14] |
Lee CC, Yamamoto S, Wanibuchi H, et al. Cyclin D1 overexpression in rat two-stage bladder carcinogenesis and its relationship with oncogenes, tumor suppressor genes, and cell proliferation[J]. Cancer Res, 1997, 57(21):4765-4776.
|
| [15] |
Bonelli P, Tuccillo FM, Borrelli A, et al. CDK/CCN and CDKI alterations for cancer prognosis and therapeutic predictivity[J]. Biomed Res Int, 2014:361020.
|
| [16] |
Akin S, Babacan T, Sarici F, et al. A novel targeted therapy in breast cancer: cyclin dependent kinase inhibitors[J]. J BUON, 2014, 19(1):42-46.
|
| [17] |
Hnit SS, Xie C, Yao M, et al. p27(Kip1) signaling: transcriptional and post-translational regulation[J]. Int J Biochem Cell Biol, 2015(68):9-14.
|
| [18] |
Nadeem L, Brkic J, Chen YF, et al. Cytoplasmic mislocalization of p27 and CDK2 mediates the anti-migratory and anti-proliferative effects of Nodal in human trophoblast cells[J]. J Cell Sci, 2013, 126(Pt 2):445-453.
|
| [19] |
Dai L, Liu Y, Liu J, et al. A novel cyclinE/cyclinA-CDK inhibitor targets p27(Kip1) degradation, cell cycle progression and cell survival: implications in cancer therapy[J]. Cancer Lett, 2013, 333(1):103-112.
|
| [20] |
He W, Wang X, Chen L, et al. A crosstalk imbalance between p27(Kip1) and its interacting molecules enhances breast carcinogenesis[J]. Cancer Biother Radiopharm, 2012, 27(7):399-402.
|